The 2026 ESC heart failure guidelines: advancing science while facilitating clinical implementation
The 2026 European Society of Cardiology (ESC) guidelines for the management of heart failure introduce a series of important changes intended to simplify classification, accelerate implementation of effective therapies, and shift care toward earlier prevention and intervention. Among the most notable changes are the incorporation of patients with mildly reduced left ventricular ejection fraction into the heart failure with reduced ejection fraction category, the replacement of the traditional concept of guideline-directed medical therapy with a three-tiered framework of foundational medical therapy, additional medical therapy, and guideline-directed interventional therapy, and greater emphasis on prevention through the formal use of stages A to D. The guidelines also favor the term “decompensated heart failure” over “acute heart failure,” reinforcing the concept that clinical deterioration often reflects an evolving process rather than an abrupt event. These changes provide a clearer and more actionable clinical pathway and emphasize rapid initiation of foundational therapies and timely referral for advanced heart failure care. At the same time, simplification may reduce phenotypic granularity, and some recommendations warrant continued discussion regarding the relationship between recommendation strength and supporting evidence. The Class I recommendation for mineralocorticoid receptor antagonists in symptomatic heart failure with preserved ejection fraction illustrates this tension, particularly given differences between steroidal and non-steroidal agents and across patient phenotypes. Overall, the 2026 ESC guidelines provide a pragmatic, forward-looking framework that may improve implementation and continuity of heart failure care. Their greatest impact, however, will depend not only on scientific rigor, but also on thoughtful interpretation, individualized application, and timely translation into everyday clinical practice.
Authors
- Gianluigi Savarese (ORCID: https://orcid.org/0000-0001-7732-0887)
- Michael Fu (ORCID: https://orcid.org/0000-0003-1636-870X)
- Karl Swedberg
Institutions
- Karolinska Institutet (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Cardiology Plus
- Published
- 2026-09-25
- DOI
- https://doi.org/10.1097/cp9.0000000000000177
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00